China holds a choke point on the global pharmaceutical supply chain, being the sole source for key ingredients in hundreds of US medicines. This leverage could be used to restrict supply, creating shortages and price hikes, opening a new, sensitive front in geopolitical tensions.

The steep tariff on foreign-made drugs is an aggressive tactic to compel pharmaceutical companies to bring manufacturing back to the US. It aims to solve two critical problems: reducing strategic dependency on adversaries like China and rebuilding domestic manufacturing jobs.

Large multinational pharma companies publicly express concern about the threat from China's biopharma sector. Simultaneously, these same companies are investing billions, actively integrating China into the global ecosystem and contradicting their own zero-sum game narrative.

US policymakers debating restrictions on China's biotech sector may be influenced by competition in industries like semiconductors and electric vehicles. This approach is flawed because it fails to recognize that the life sciences industry is fundamentally different, with unique dynamics in innovation, IP, and global collaboration that don't map directly from other technology sectors.

A disconnect exists between the public rhetoric of U.S. pharma leaders, who frame China's growing biotech sector as a threat, and their corporate actions. These same companies are investing heavily in Chinese R&D and manufacturing, revealing a dual strategy of public caution and private commitment to integrating China into the global biopharma ecosystem.

As it becomes easier and more efficient to run clinical trials in China, U.S. companies are increasingly outsourcing them. This creates a dependency where China could cut off access to trials or withhold critical new drugs, ceding the entire innovation edge.

Beyond just pharma, China is engaging in a 'salami slicing' strategy to take over the foundational infrastructure of the U.S. biotech economy. This slow, incremental acquisition of manufacturing and research capabilities mirrors its successful long-term strategy for dominating sectors like rare earths.

A major obstacle to securing U.S. supply chains is a deliberate lack of data. The government has avoided mandating data collection on critical dependencies, like pharmaceutical ingredients from China, out of deference to industry. This prevents policymakers from even understanding the extent of their vulnerabilities.

The old narrative of China's IP theft is outdated. Today, China's competitive advantage in sectors like biotech comes from its massive scale, significant resources, and collective lack of profit sensitivity. This combination allows it to dominate industries and destroy profitability for other global players, as previously seen in solar and EVs.